Choosing an Eradication Regimen After a Year of Clarithromycin Exposure
A single patient with a fresh H. pylori diagnosis and no resistance test in hand. The disagreement isn't about which regimen works — both do — it's about how much weight one prior antibiotic course should carry when the alternative to guessing right is a guideline-standard regimen built specifically not to need the guess at all.
Daniela R., a 41-year-old high school chemistry teacher, has spent the last two months treating her burning midepigastric pain as a grading-season inevitability, the same way she treats her own sinus infections — something to push through until the semester breaks. It was a colleague, not a doctor, who finally talked her into a stool antigen test, and it came back positive for Helicobacter pylori. She has never had an ulcer worked up before, has no alarm features (no weight loss, no bleeding, no dysphagia), and is otherwise healthy apart from hypothyroidism controlled on levothyroxine.
What actually complicates her regimen choice is a detail she almost didn't mention: a course of azithromycin, ten months ago, for a sinus infection her PCP diagnosed clinically without a culture. Azithromycin and clarithromycin are both macrolides, and prior macrolide exposure of any kind is one of the strongest individual predictors of pre-existing clarithromycin-resistant H. pylori — not because the drugs cross-react pharmacologically, but because a macrolide-exposed bacterial population has already been selected for the 23S rRNA mutations that confer resistance to the whole class. Standard PPI-based clarithromycin triple therapy, offered reflexively as first-line for decades, is exactly the regimen whose efficacy collapses fastest against a resistant strain.
Vonoprazan, a potassium-competitive acid blocker, was compared directly against a lansoprazole-based triple regimen in the pivotal U.S. Phase 3 trial (Chey et al., 2022) and the two performed similarly overall — but the trial's own subgroup analysis is the part that actually bears on Daniela: in patients with confirmed clarithromycin-resistant strains, vonoprazan-based therapy eradicated infection at meaningfully higher rates than the PPI-based comparator, a gap the overall topline result understates. She has never had resistance testing done, and the group has to decide whether her exposure history is reason enough to act as if she already has it. Resistance testing itself — either culture-based susceptibility or molecular PCR-based detection of the resistance mutation directly — exists, but isn't readily available at this clinic on a turnaround that would help today, which is exactly the gap that makes her exposure history the only real signal in hand.
Deciding without a resistance test in hand
Her azithromycin course ten months ago is the single most useful piece of history in this chart, and I don't think it should be treated as incidental. Prior macrolide exposure of any kind selects for the 23S rRNA mutations that drive clarithromycin resistance in H. pylori — the bacteria don't care which macrolide selected them.
Chey et al.'s 2022 Phase 3 trial is the real comparison here: vonoprazan-based triple therapy against lansoprazole-based triple therapy. Overall eradication rates were similar, which is the number everyone quotes — but the trial's own subgroup analysis in clarithromycin-resistant isolates showed vonoprazan holding its efficacy where the PPI arm's fell off. That's the population she's actually in.
I don't disagree with the mechanism, and I'm not arguing the trial data are wrong. What I'd push back on is treating one macrolide exposure ten months ago as equivalent to a positive resistance test.
You're right that the selection pressure is real — but we don't actually know her strain's susceptibility, and bismuth quadruple therapy doesn't need us to know it. It's the AGA and Maastricht VI-recommended regimen specifically for patients where clarithromycin resistance is suspected but unconfirmed, and its four-drug mechanism — bismuth's direct mucosal and antibacterial action, tetracycline, and metronidazole — has no clarithromycin susceptibility dependence to fail against.
That's a fair distinction — exposure history is a proxy, not a genotype. But I'd note the two positions converge more than they look like they do: bismuth quadruple therapy is a genuinely reasonable choice here, not a fallback. I'd only push toward vonoprazan-based therapy specifically if bismuth were unavailable or poorly tolerated — tetracycline dosing four times daily is a real adherence risk in someone managing a full teaching schedule.
Bismuth quadruple therapy for 14 days, with explicit counseling on the four-times-daily tetracycline dosing and a written pill schedule she can keep at school.
Not fully settled: whether her exposure history alone should ever be sufficient grounds to skip straight to vonoprazan-based therapy in a patient for whom bismuth quadruple therapy is genuinely inconvenient or poorly tolerated. The Gastroenterologist's position carried the day today because bismuth quadruple therapy was a real, guideline-supported option available to her — not because the Clinical Pharmacologist's reading of the resistance data was judged wrong.